Oncogenomics

Bionano Featured at Cancer Genomics Consortium Annual Meeting with Multiple Data Readouts that Further Validate Saphyr in the Field of Cytogenetics and Lay Groundwork for a Novel LDT in Cancer

Retrieved on: 
Monday, August 10, 2020
Branches of biology, Genetics, Biology, Biotechnology, Molecular biology, Molecular genetics, Cancer, Genome, Oncogenomics, Cytogenetics

The Cancer Genomics Consortium (CGC) is an organization comprised of leading cytogeneticists, molecular geneticists and molecular pathologists.

Key Points: 
  • The Cancer Genomics Consortium (CGC) is an organization comprised of leading cytogeneticists, molecular geneticists and molecular pathologists.
  • Its annual meeting attracts the key opinion leaders and cytogenetics directors from North Americas leading cancer centers and hospitals.
  • In the last several years, the meeting has seen an increasing presence of studies and presentations featuring data generated using Bionanos Saphyr genome imaging system.
  • In a second child with similar disease, Saphyr called five extra copies of the same oncogene, while CMA called only 2.

Black Diamond Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, August 5, 2020
Biotechnology, Medical genetics, Biology, Applied genetics, Life sciences, Cancer, RTT, Oncogenomics, Academic disciplines

Live webcasts of each presentation can be accessed by visiting the investor relations section of the Companys website, www.blackdiamondtherapeutics.com .

Key Points: 
  • Live webcasts of each presentation can be accessed by visiting the investor relations section of the Companys website, www.blackdiamondtherapeutics.com .
  • Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies.
  • Black Diamond targets undrugged mutations in patients with genetically defined cancers.
  • Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics

Retrieved on: 
Tuesday, June 30, 2020
Branches of biology, Biology, Biotechnology, Life sciences, Medical genetics, Evidence-based medicine, Precision medicine, Systems biology, Molecular diagnostics, Oncogenomics, Synthetic lethality, Oncology

Through these roles, Dr. Hampton has become a thought leader in the area of precision medicine oncology, including next generation sequencing, cancer genomics, and companion diagnostics.

Key Points: 
  • Through these roles, Dr. Hampton has become a thought leader in the area of precision medicine oncology, including next generation sequencing, cancer genomics, and companion diagnostics.
  • IDEAYA believes global access to molecular diagnostics for oncology patients, particularly in Asia, is key to the development of targeted oncology medicines.
  • "IDEAYA is a leader in Synthetic Lethality, an emerging field of precision medicine oncology.
  • IDEAYA is applying these capabilities across multiple classes of precision medicine, including synthetic lethality which represents an emerging class of precision medicine targets.

Personalis Announces New Data to be Presented at AACR Virtual Scientific Meeting

Retrieved on: 
Monday, June 22, 2020
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Biotechnology, Medical genetics, Applied genetics, Oncogenomics

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.

Key Points: 
  • Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.
  • Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes.
  • The Personalis Clinical Laboratory is GxP-aligned as well as CLIA88-certified and CAP-accredited.
  • For more information, please visit www.personalis.com and follow Personalis on Twitter ( @PersonalisInc ).

Personalis to Participate in European Association for Cancer Research (EACR) 2020 Virtual Congress

Retrieved on: 
Thursday, June 18, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, Branches of biology, Biology, Genetics, Biotechnology, Applied genetics, Gene expression, RNA, Transcriptome, Cancer research, Oncogenomics, Biomarker discovery, Cancer

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the companys participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020.

Key Points: 
  • Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the companys participation in the European Association for Cancer Research (EACR) 2020 Virtual Congress, which will be held online, June 18-19, 2020.
  • Personalis will present Enabling Composite Biomarker Discovery for Precision Cancer Therapy with an Enhanced Exome and Transcriptome Platform in an industry-sponsored symposium , featuring the Personalis universal cancer immunogenomics platform, ImmunoID NeXT .
  • Erin Newburn, MS, PhD, will present for Personalis.
  • Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.

Personalis to Present at the Precision Breast Cancer Summit

Retrieved on: 
Tuesday, June 16, 2020
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, Branches of biology, Medicine, Biotechnology, Clinical medicine, Biomarkers, Chemical pathology, Medical signs, Oncogenomics, Cancer, Brachyury

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the companys participation at the Precision: Breast Cancer Summit, which will be held online, June 16-17, 2020.

Key Points: 
  • Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the companys participation at the Precision: Breast Cancer Summit, which will be held online, June 16-17, 2020.
  • Personalis will present Enabling multidimensional tumor immunogenomics for advancing biomarker discovery, featuring the Personalis universal cancer immunogenomics platform, ImmunoID NeXT TM.
  • Christelle Johnson, PhD, will present for Personalis.
  • Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.

Onconova Therapeutics Announces Presentation at the 25th Congress of the European Hematology Association (EHA)

Retrieved on: 
Friday, June 12, 2020
Branches of biology, Oncogenes, Ras GTPase, Cancer, Biology, Applied genetics, Pelareorep, Oncogenomics

Mutations in RAS Pathway Genes Correlate with Type of Failure to Azacitidine: Genomic Analysis at Randomization onto the Inspire Trial.

Key Points: 
  • Mutations in RAS Pathway Genes Correlate with Type of Failure to Azacitidine: Genomic Analysis at Randomization onto the Inspire Trial.
  • In total, 55 different mutations were identified at baseline, with the median number of mutations per patient at 3.
  • RAS pathway mutations were observed more frequently in patients that progressed on HMA therapy than those that failed HMA therapy completely.
  • Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells.

Personalis, Inc. Announces New Data to be Presented at ASCO Virtual Scientific Meeting

Retrieved on: 
Friday, May 29, 2020
Oncology, Health, Genetics, Research, Science, Biotechnology, Branches of biology, Genetics, Biology, Biotechnology, Genomics, Medical genetics, Applied genetics, Oncogenomics, Genome

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.

Key Points: 
  • Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.
  • Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes.
  • The Personalis Clinical Laboratory is GxP-aligned as well as CLIA88-certified and CAP-accredited.
  • For example, forward-looking statements include statements regarding the future availability, features or potential uses of the ImmunoID NeXT Platform or NeXT Dx Test and other future events.

Personalis to Participate at the Cowen 40th Annual Health Care Conference

Retrieved on: 
Tuesday, February 18, 2020
Biotechnology, Health, Oncology, Biotechnology, Oncogenomics

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate at the upcoming Cowen 40th Annual Health Care Conference.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that company management will participate at the upcoming Cowen 40th Annual Health Care Conference.
  • John West, Chief Executive Officer, will be presenting on Wednesday, March 4, 2020 at 8:40 a.m. Eastern Time at the Boston Marriott Copley Place hotel in Boston.
  • Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patients cancer and immune response.
  • Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes.

The global tumor (cancer) profiling market at a CAGR of over 10% during the forecast period

Retrieved on: 
Friday, January 17, 2020
Branches of biology, Biology, Genetics, Biotechnology, Data mining, Identity, Identity management, Profiling, Medical genetics, Oncogenomics

Global Tumor (Cancer) Profiling Market: About this market

Key Points: 
  • Global Tumor (Cancer) Profiling Market: About this market
    This tumor (cancer) profiling market analysis considers sales from immunoassays, next-generation sequencing, polymerase chain reaction, and in-situ hybridization technologies.
  • Also, our global tumor (cancer) profiling market report looks at factors such as increasing incidences of cancer, low cost of genetic sequencing, and increasing awareness about tumor profiling.
  • Global Tumor (Cancer) Profiling Market: Overview
    Various government and private organizations and companies are creating awareness about the significance of tumor profiling, its diagnosis and personalized treatment of cancer.
  • Thus, increasing awareness about tumor profiling will lead to the expansion of the global tumor (cancer) profiling market at a CAGR of over 10% during the forecast period.